Physician profile
Eric E Mast
NPI 1437156296
$1,808.19
in general payments reported to CMS, 2019-2025
28 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.15 · 2020: $72.85 · 2021: $51.15 · 2022: $219 · 2023: $494 · 2024: $671 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $622.44 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $220.77 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $214.45 | 2019-2025 | |
| Novo Nordisk INC | $76.62 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $64.62 | 2019-2024 | Jardiance, Mounjaro |
| Exact Sciences Corporation | $63.09 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.69 | 2023-2024 | Jardiance |
| Inspire Medical Systems, INC. | $50.13 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $44.94 | 2020-2021 | |
| Abbott Laboratories | $37.11 | 2024 | Freestyle Libre 3 |
| Cranial Technologies, INC | $32.73 | 2023 | Doc Band |
| Amgen INC. | $32.40 | 2024 | Repatha, Otezla |
| Dexcom, INC. | $26.73 | 2025 | Dexcom G6 Transmitter |
| Pacira Pharmaceuticals Incorporated | $26.56 | 2024 | Exparel, Iovera, Zilretta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.31 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.49 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.98 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.38 | 2025 | Caplyta |
| Boston Scientific Corporation | $18.16 | 2024 | |
| Gilead Sciences, INC. | $17.93 | 2023 | |
| Glaxosmithkline, LLC. | $15.03 | 2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $14.27 | 2023 | |
| Sanofi Pasteur INC. | $13.88 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.37 | 2024 | Rexulti |
| Organon LLC | $12.82 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Mast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.